Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer

Benedikt Hoeh a, b, *, Rocco Flammia b, c, Lukas Hohenhorst b, d, Gabriele Sorce b, e, Francesco Chiocchio b, f, Zhe Tian b, Fred Saad b, Michele Gallucci c, Alberto Briganti e, Carlo Terrone i, Shahrokh F. Shariat g, h, j, k, l, Markus Graeven d, Derya Tilki d, m, n, Luis A. Kluth a, Philipp Mandel a, Felix K.H. Chun a, Pierre I. Karakiewicz b

a Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Am Main, Frankfurt Am Main, Germany
b Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
c Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
d Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
e Department of Urology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
f Division of Experimental Oncology/Unit of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy
g Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
h Department of Urology, Weill Cornell Medical College, New York, NY, USA
i Department of Urology, University of Texas Southwestern, Dallas, TX, USA
j Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
k Institute for Urology and Reproductive Health, IM. Sechenov First Moscow State Medical University, Moscow, Russia
l Institute of Urology, University of Genova, Genova, Italy
m Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
n Department of Urology, Koc University Hospital, Istanbul, Turkey

ARTICLE INFO

Article history:
Received 14 December 2021
Received in revised form 10 January 2022
Accepted 17 January 2022
Available online 26 January 2022

Keywords:
Downgrading
Intermediate-risk
Prostate cancer
Single positive biopsy core
Upgrading

ABSTRACT

Background: Up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown.

Methods: We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (< cT2c and PSA < 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010–2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading.

Results: Of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; p = 0.3) and median age (62 vs 63 years; p = 0.07) and cT1-stage (77 vs 75%; p = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10–20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR: 2.89; 95%-CI: 1.31–6.11; p = 0.007).

Conclusion: In single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.

© 2022 Asian Pacific Prostate Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Prostate cancer (PCa) patients with single intermediate-risk positive biopsy core and without other high-risk features pose a therapeutic dilemma, since the rates of high-risk grading features at definite therapy are unknown.1–4 More precisely, the rates of
Gleason grade group (GGG) agreement and more or less favorable GGG at radical prostatectomy (RP) are virtually unknown in the subgroup of single GGG2 or GGG3 positive biopsy core. Exception consists of three methodologically limited and small-scaled studies that provided a potentially biased perspective of upgrading rates in single core positive patients. To fill this current knowledge gap, we addressed this void and hypothesized that virtually all single intermediate-risk positive biopsy core patients will not harbor high-risk GGG features at RP. We tested this hypothesis in the Surveillance, Epidemiology, and End Results (SEER) database (2010–2015) and specifically tested for rates in grade agreement, up- and downgrading between biopsy versus radical prostatectomy pathology.

2. Material and methods

2.1. Study population

The current SEER database samples 34.6% of the United States population and approximates it in demographic composition and cancer incidence. Within SEER database 2010–2015, we identified all patients ≥18-years-old with histologically confirmed adenocarcinoma of the prostate, diagnosed at biopsy (International Classification of Disease for Oncology [ICD-O-3] code 8140 site code C61.9). We included all patients with a single positive core at biopsy harboring GGG2 or GGG3 who underwent RP. Exclusion criteria consisted of less than 10 or more than 14 biopsy cores, unknown prostate-specific antigen (PSA)/clinical T-stage or presence of high-risk PSA (>20 ng/mL) or clinical T-stage features according to the National Comprehensive Cancer Network (NCCN) prostate cancer guidelines. Furthermore, cases identified only at autopsy or death certificate or with unknown histology were excluded. These selection criteria resulted in a cohort of 1,328 assessable NCCN intermediate-risk PCa patients.

2.2. Statistical analyses

Descriptive statistics included frequencies and proportions for categorical variables. Means, medians, and interquartile ranges (IQR) were reported for continuously coded variables. The Chi-square tested the statistical significance in proportions’ differences. The t-test and Kruskal–Wallis test examined the statistical significance of means’ and distributions’ differences. Statistical analyses were based on three steps. First, baseline characteristics were tabulated according to GGG2 versus GGG3 at biopsy. Second, rates of GGG agreement, up- and downgrading were tabulated. Finally, separate univariable and multivariable logistic regression models tested for independent predictors (PSA [<10 ng/mL vs 10–20 ng/mL]; clinical T-stage [cT1 vs cT2]) for upgrading and downgrading in GGG2 versus GGG3 single core positive patients, respectively. Hereby, upgrading was defined as an increase of GGG at RP relative to GGG at biopsy and downgrading as decrease of GGG at RP relative to GGG at biopsy. Additional covariates consisted of age (per year), numbers of cores at biopsy (continuously coded) and year of diagnosis (continuously coded). All tests were two sided with a level of significance set at p < 0.05 and R software environment for statistical computing and graphics (version 3.4.3) was used for all analyses.

Table 1

| Overall, n = 1,328 | GGG2, n = 972 (73.3%) | GGG3, n = 356 (26.8%) | P-value |
|------------------|---------------------|---------------------|---------|
| **Age in years, median (IQR)** | 62 (57, 66) | 62 (57, 66) | 63 (58, 67) | 0.071 |
| **PSA in ng/mL, median (IQR)** | 5.6 (4.4, 7.6) | 5.5 (4.4, 7.6) | 5.7 (4.6, 7.4) | 0.2 |
| PSA (grouped) in ng/mL, median (IQR) | 1,163 (88%) | 857 (88%) | 306 (86%) | 0.3 |
| **Year of diagnosis, n (%)** | 165 (12%) | 115 (12%) | 50 (14%) | 0.13 |
| 2010 | 226 (17%) | 180 (19%) | 46 (13%) |
| 2011 | 217 (16%) | 162 (17%) | 55 (15%) |
| 2012 | 231 (17%) | 161 (17%) | 70 (20%) |
| 2013 | 233 (18%) | 162 (17%) | 71 (20%) |
| 2014 | 203 (15%) | 151 (16%) | 52 (15%) |
| 2015 | 218 (16%) | 156 (16%) | 62 (17%) |
| **cT-stage, n (%)** | | | 0.4 |
| cT1c | 1,019 (77%) | 753 (77%) | 266 (75%) |
| cT2a | 105 (7.9%) | 71 (7.3%) | 34 (9.6%) |
| cT2b | 3 (0.2%) | 2 (0.2%) | 1 (0.3%) |
| cT2c | 32 (2.4%) | 22 (2.3%) | 10 (2.8%) |
| cT2x | 169 (13%) | 124 (13%) | 45 (13%) |
| **cT-stage combined, n (%)** | | | 0.3 |
| cT1 | 1,019 (77%) | 753 (77%) | 266 (75%) |
| cT2 | 309 (23%) | 219 (23%) | 90 (25%) |
| **Number of biopsy cores, n (%)** | | | 0.2 |
| 10 | 72 (5.4%) | 50 (5.1%) | 22 (6.2%) |
| 11 | 21 (1.6%) | 13 (1.3%) | 8 (2.2%) |
| 12 | 1025 (77%) | 705 (79%) | 260 (73%) |
| 13 | 79 (5.9%) | 57 (5.9%) | 22 (6.2%) |
| 14 | 131 (9.9%) | 87 (9.0%) | 44 (12%) |
| **GGG RP-specimen, n (%)** | | | <0.001 |
| 1 | 227 (17%) | 191 (20%) | 36 (10%) |
| 2 | 744 (56%) | 616 (63%) | 128 (36%) |
| 3 | 280 (21%) | 130 (13%) | 150 (42%) |
| 4 | 52 (3.9%) | 27 (2.8%) | 25 (7.0%) |
| 5 | 25 (1.9%) | 8 (0.8%) | 17 (4.8%) |

Abbreviations: GGG – Gleason Grade Group; PSA – Prostate-specific antigen; RP – Radical prostatectomy; IQR – Interquartile range
3. Results

3.1. Descriptive characteristics of the study population

Between 2010 - 2015, we identified 1328 assessable NCCN intermediate-risk PCA patients with a single positive core of GGG2 or GGG3 at biopsy (Table 1 and Fig. 1). Of those, 972 (73.3%) harbored GGG2 at biopsy, whereas 356 (26.8%) GGG3, respectively. Median age was 62 (IQR: 57–66) versus 63 years (IQR: 58–67) and median PSA was 5.5 (IQR: 4.4–7.6) versus 5.7 ng/mL (IQR: 4.6–7.4) for GGG2 versus GGG3 patients, respectively (both p > 0.05). Median number of cores was 12 (IQR: 12–12) and did not differ between both groups. At RP-specimen, GGG1 was 20 versus 10%, GGG2 63 versus 36%, GGG3 13 versus 42%, GGG4 3 versus 7% and GGG5 1 versus 5% for GGG2 versus GGG3 at biopsy, respectively (p < 0.001).

3.2. Rates of up- and downgrading in single GGG2 positive biopsy core PCA patients

Of 972 patients with single GGG2 positive core at biopsy, 616 patients (63%) also exhibited GGG2 versus 191 (20%) GGG1 at RP. Of GGG2 patients, 165 (17%) exhibited higher GGG at RP: 130 GGG3 (13%) versus 27 GGG4 (3%) versus 8 GGG5 (1%) patients at RP, respectively (Fig. 2a).

3.3. Rates of up- and downgrading in single GGG3 positive biopsy core PCA patients

Of 356 patients with single GGG3 positive core at biopsy, 150 patients (42%) also exhibited GGG3 versus 128 GGG2 (36%) versus 36 GGG1 (10%) at RP. Of GGG3 patients, 42 (12%) exhibited higher GGG at RP: 25 GGG4 (7%) versus 17 GGG5 (5%) patients at RP, respectively (Fig. 2b).
3.4. Effect of clinical variables on changes in GGG pattern in RP-specimen

In uni- and multivariable logistic regression models predicting downgrading in GGG2 patients, age was a modest, independent predictor of downgrading (multivariable OR: 0.94; 95%-CI: 0.93–0.97; \( p < 0.001 \)). Other covariates failed to reach independent predictor status for up- or downgrading in GGG2 (Table 2). Conversely, in uni- and multivariable logistic regression models predicting upgrading in GGG3, PSA of 10–20 ng/mL was an independent, strong risk factor for upgrading in GGG RP-specimen in both uni- and multivariable logistic regression models (multivariable OR: 2.89; 95%-CI: 1.31–6.11; \( p = 0.007 \)). Furthermore, year of diagnosis was an independent predictor for downgrading in GGG3 in both univariable and multivariable logistic regression models (multivariable OR: 0.78; 95%-CI: 0.62–0.97; \( p = 0.03 \)). Other covariates failed to reach independent predictor status for up- or downgrading in GGG3 (Table 3).

4. Discussion

The rates of upgrading, grade agreement and downgrading between Gleason Grade groups at biopsy versus RP in PCa patients with a single intermediate-risk (GGG2 or GGG3) positive biopsy core are unknown. We hypothesized that virtually all such patients will harbor the same or lower GGG at RP. We tested this hypothesis in two specific cohorts, namely single GGG2 positive core versus single GGG3 positive core at biopsy, respectively. We relied on SEER database (2010–2015) and made some noteworthy findings.

First, the overall number of individuals with clinically localized, intermediate-risk prostate cancer (≤ cT2c and PSA ≤ 20 ng/mL) and single positive core at biopsy was substantial (\( n = 18,469 \)) in the study population between 2010 and 2015. Of those, 4,818 (27%) patients underwent RP as active treatment choice. Interestingly, among those patients who underwent RP, GGG2 or GGG3 was present as a single positive core at biopsy in 28% of the cases (Fig. 1). In consequence, the combination of a single intermediate-risk positive core at biopsy with lack of further high-risk features in PCa patients does not represent a rare entity and is of high importance, since the appropriate treatment choice among those specific patient group is still an ongoing debate.\(^{10–12} \)

Second, we did not identify either statistically significant or clinically meaningful differences in baseline prostate cancer characteristics between single GGG2 positive biopsy core and GGG3 in intermediate-risk patients, respectively. In consequence, other prostate cancer characteristics are not helpful in distinguishing between these two specific patients' groups.
### Table 2
Separate univariable and multivariable logistic regression models testing for independent predictors for down and upgrading in single GGG2 positive core at biopsy in prostate cancer patients treated with radical prostatectomy within the surveillance, epidemiology, and end results (SEER) database (2010–2015)

|                      | Downgrading to GGG1 | Upgrading to GGG4/GGG5 |
|----------------------|---------------------|------------------------|
|                      | Univariable         | Multivariable          | Univariable          | Multivariable          |
|                      | Odds Ratio 2.5% 97.5% P-value | Odds Ratio 2.5% 97.5% P-value | Odds Ratio 2.5% 97.5% P-value | Odds Ratio 2.5% 97.5% P-value |
| PSA < 10 ng/mL       | Ref.                | Ref.                   | Ref.                 | Ref.                   |
| PSA 10–20 ng/mL      | 0.49                | 0.26 0.86 0.02         | 0.60 0.31 1.08 0.11   | 2.30 0.95 4.97 0.045    | 2.12 0.86 4.72 0.08 |
| Numbers of biopsy cores | 0.89              | 0.72 1.09 0.25         | 0.90 0.73 1.11 0.33   | 1.19 0.78 1.79 0.41     | 1.16 0.76 1.74 0.49 |
| cT1c-stage           | Ref.                | Ref.                   | Ref.                 | Ref.                   |
| cT2-stage            | 1.16                | 0.79 1.66 0.44         | 1.23 0.84 1.79 0.28   | 1.39 0.63 2.86 0.39     | 1.40 0.63 2.91 0.38 |
| Age                  | 0.95                | 0.92 0.97 < 0.001      | 0.94 0.93 0.97 < 0.001 | 1.03 0.98 1.09 0.22     | 1.02 0.97 1.08 0.44 |
| Year of diagnosis    | 0.91                | 0.83 0.99 0.04         | 0.92 0.84 1.01 0.08   | 1.10 0.90 1.34 0.36     | 1.08 0.88 1.32 0.47 |

Abbreviations: PSA = Prostate-specific antigen

### Table 3
Separate univariable and multivariable logistic regression models testing for independent predictors for down and upgrading in single GGG3 positive core at biopsy in prostate cancer patients treated with radical prostatectomy within the surveillance, epidemiology, and end results (SEER) database (2010–2015)

|                      | Downgrading to GGG1 | Upgrading to GGG4/GGG5 |
|----------------------|---------------------|------------------------|
|                      | Univariable         | Multivariable          | Univariable          | Multivariable          |
|                      | Odds Ratio 2.5% 97.5% P-value | Odds Ratio 2.5% 97.5% P-value | Odds Ratio 2.5% 97.5% P-value | Odds Ratio 2.5% 97.5% P-value |
| PSA < 10 ng/mL       | Ref.                | Ref.                   | Ref.                 | Ref.                   |
| PSA 10–20 ng/mL      | 0.33                | 0.05 1.15 0.14         | 0.39 0.06 1.36 0.21   | 3.36 1.57 6.93 0.001    | 2.89 1.31 6.11 0.007 |
| Numbers of biopsy cores | 0.83              | 0.56 1.22 0.34         | 0.86 0.58 1.28 0.47   | 0.94 0.65 1.35 0.73     | 0.94 0.64 1.36 0.74 |
| cT1c-stage           | Ref.                | Ref.                   | Ref.                 | Ref.                   |
| cT2-stage            | 0.98                | 0.42 2.11 0.97         | 1.05 0.44 2.31 0.90   | 0.67 0.28 1.43 0.33     | 0.64 0.26 1.44 0.31 |
| Age                  | 0.99                | 0.94 1.04 0.55         | 0.99 0.94 1.05 0.77   | 1.06 1.01 1.11 0.03     | 1.04 0.99 1.10 0.10 |
| Year of diagnosis    | 0.76                | 0.61 0.95 0.02         | 0.78 0.62 0.97 0.03   | 1.25 1.03 1.55 0.03     | 1.21 0.99 1.51 0.07 |

Abbreviations: PSA = Prostate-specific antigen
Third, in single GGG2 positive biopsy core patients, only 4% harbored high-risk GGG features at RP (GGG4: 3% vs GGG5: 1%). In those patients, the presence of GGG4 or GGG5 at RP would virtually invariably imply treatment modifications. In EBRT candidates, administration of ADT of long duration would be recommended, in RP candidates, an extended lymphadenectomy should invariably be considered.13,14 Additionally, a small proportion harbored GGG3 at RP (13%). In those individuals, fewer treatment applications would be applicable. Nonetheless, ADT treatment of short duration and extended pelvic lymph node dissection might also be required.15,16 Moreover, the vast majority (63%) of GGG2 patients exhibited a GGG agreement at RP. Interestingly, an intermediate sized-group (20%) exhibited GGG1 at RP, where conservative management could have been applied in regards to GGG risk.20,26 Taken together, in single GGG2 positive biopsy core patients, very few individuals with significantly more aggressive GGG were identified. Nonetheless, an intermediate proportion of individuals with favorable grade were identified. In consequence, it may be argued that definite treatment in single GGG2 positive biopsy core patients will at least overtreat 20% of such individuals based on GGG1 features.

Fourth, trends in single GGG3 positive biopsy core patients significantly differed from those in GGG2 patients. In 12% of GGG3 patients, final RP pathology revealed the presence of GGG4 (7%) or GGG5 (5%), demonstrating a clinically meaningful upgrading to high-risk grade features. Changes in treatment modalities which were previously extrapolated for upgrading in GGG2 patients, account equally for GGG3 patients. It is of note that elevated PSA at diagnosis (>10 ng/mL) was a strong risk factor in multivariable logistic regression models predicting upgrading in single GGG3 positive biopsy core patients (OR: 2.89). As a consequence, preoperative PSA independently predicted upgrading in GGG3 and should be considered of utmost importance in treatment decision making, within this specific subgroup of single GGG3 positive biopsy core patients. Furthermore, grade agreement in GGG3 patients was present in 42% patients. Interestingly in single GGG3 positive biopsy core, a smaller, yet considerably sized group of 36% patients exhibited GGG2 features in RP pathology. Moreover, a fairly small proportion (10%) of GGG3 patients exhibited GGG1 at final RP pathology. Consequently, overtreatment in single GGG3 positive biopsy core patients may have occurred based on grade downgrading in at least one out of ten patients.

The current study is not devoid of limitations. First, it reflects the selection bias inherent in a surgical cohort. Second, despite extensive multivariable adjustments, we were unable to adjust for potential important baseline characteristics not recorded in SEER, such as imaging findings (e.g., MRI), PSA density, family history, and potential bias arising from methodological differences in the process of specimen procurement, fixation, and histopathological analyses.23–26 These limitations apply to both the biopsy and RP specimen equally. It is of note that this limitation is inherent to other population-based databases.27 Finally, exact data regarding potential differences in biopsy mapping templates are not available and might demonstrate a bias. To minimize potential biases that are likely to arise from different biopsy templates and consequently different numbers of biopsy cores taken, we included only patients with ten to fourteen cores harbored at biopsy. By relying on this very strict inclusion criteria, confounding due to a heterogeneity in number of cores was reduced in the best possible approach.

5. Conclusions

In single core positive GGG2 patients, a marginal fraction will exhibit high-risk GGG at RP. The vast majority will exhibit the same GGG and a minority will harbor GGG1 at RP. Conversely, in single core positive GGG3 patients, the majority will harbor lower GGG at RP. An equally sized group will harbor the same GGG and a minority will harbor high-risk GGG4 and GGG5 at RP. In the future, large-scale studies are needed to confirm these findings in the context of MRI-guided single intermediate-risk positive biopsy core.

Data availability statement

All data generated for this analysis were from the SEER database. The code for the analyses will be made available upon request.

Ethics consent statement

All analyses and their reporting followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study-specific Institutional Review Board’s ethics approval was not required.

Funding statement

The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Patient consent statement, permission to reproduce material from other sources and clinical trial registration

Not applicable

Conflicts of interest

The authors declare that there is no conflict of interests.

Acknowledgments

B.H. was awarded a scholarship by the STIFTUNG GIERSCH.

References

1. Masic S, Cowan JE, Washington SL, Nguyen HG, Shinhara K, Cooperberg MR, et al. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. European Urology Oncology 2018 Oct;1(5):386–94.
2. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017 Apr;71(4):630–42.
3. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis RJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2019 May;17(5):479–505.
4. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA 2015 Jul 7;314(1):90.
5. Yamamoto H, Koei T, Okuboto T, Mitsuzuka K, Narita S, Inoue T, et al. Can single positive core prostate cancer at biopsy be considered a low-risk disease? Int Urol Nephrol 2018 Oct;50(10):1829–33.
6. Silva FX da, Dall’Oglio MF, Sant’ana AC, Pontes Junior J, Srougi M. Can Single Positive Core Prostate Cancer at biopsy be Considered a Low-Risk disease? Int Urol Nephrol 2018 Oct;50(10):1829–33.
7. Chaux A, Fajardo DA, Gonzalez-Robon N, Partin AW, Eisenberger M, D’Amico AV, et al. Intermediate-Risk Prostate Adenocarcinoma Present in a Single Biopsy Core is Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgical Margins at Prostatectomy. Urology 2012 Apr;79(4):863–8.
8. About the SEER Program [Internet]. SEER. [cited 2021 April 20]. Available from: https://seer.cancer.gov/about/overview.html.
9. RCT: R: A language and environment for statistical computing; 2017 https://www-projectR.org2017.
10. Mettler N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. EAU Guidelines for Prostate Cancer. In: presented at the EAU Annual Congress Amsterdam 2020 2020.
11. Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, et al. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol 2020 Jun;3(3):270–80.
12. Kane CJ, Eggener SE, Shindel AW, Andriole GL. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International
Society of Urological Pathology Gleason Group 2—3) and Implications for Risk Stratification: A Systematic Review. European Urology Focus 2017 Oct;3(4–5): 487–97.

13. Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. Eur Urol 2012 Mar;61(3):480–7.

14. Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell’Oglio P, Bravi CA, et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol 2017 Oct;72(4):632–40.

15. James ND, Sydes MR, Clarke NW, Deanesly DP, Speirs MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multinational, platform randomised controlled trial. Lancet 2016 Mar;387(10024):1163–77.

16. Krauss D, Kestin L, Ye H, Brabbins D, Chilezan M, Gustafson G, et al. Lack of Benefit for the Addition of Androgen Deprivation Therapy to Dose-Escalated Radiotherapy in the Treatment of Intermediate- and High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2011 Jul;81(4):1064–71.

17. Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, et al. An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94–13, With Emphasis on Unexpected Hormone/Radiation Interactions. Int J Radiat Oncol Biol Phys 2007 Nov;69(3):646–55.

18. D’Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial [Internet] JAMA 2008 Jan 23;299(3) [cited 2021 Sep 7]. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.299.3.289.

19. Roach M, Bae K, Speight J, Wolkow HB, Rubin P, Lee RJ, et al. Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610. J Clin Oncol 2008 Feb;1(26):585–91.

20. Toosian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol 2015 Oct 20;33(30):3379–85.

21. Chandrasekar T, Herrera-Caceres JD, Klotz L. Active surveillance in intermediate-risk prostate cancer. Arch Esp Urol 2019 Mar;72(2):157–66.

22. Klotz L. Active surveillance in intermediate-risk prostate cancer: AS for intermediate-risk PCa. BJU Int 2020 Mar;125(3):346–54.

23. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2015 Oct;1.

24. Mandel P, Wenzel M, Hoeh B, Welte MN, Preisser F, Inam T, et al. Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. Curr Oncol 2021 Jun 9;28(3):2123–33.

25. Wenzel M, Preisser F, Wittier C, Hoeh B, Wild PJ, Tschabunin A, et al. Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics 2021 May 15;11(5):882.

26. Cham K, Carle C, Hughes S, Kench JC, Woo HH, Lord S, et al. Use of multi-parametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios. Prostate Cancer Prostatic Dis 2021 Sep;24(3):662–73.

27. Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, et al. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance [Internet] Urol Oncol: Seminars and Original Investigations; 2021 May 13 [cited 2021 Sep 7]; Available from: https://www.sciencedirect.com/science/article/pii/S1078143921001605.